Following our meeting on September 20th, 2017, we actively explored the options to use the stock of human recombinant insulin that xxxx purchased from xxxxx after the discontinuation of your alliancepartnership with them.

After a thorough evaluation of all criteria, the xxxxx management chose to decline the option to buy this stock.

We thank you again for the clear explanations you have provided to us and for having offered this opportunity to Amphastar.